Biotech stock with a focus on repairing degenerative illness.
IPO’d this year at $13 dollars up to around $18 at the moment. Have a drug for a hearing loss currently in second phase testing with fast-track status with the FDA. Very unique treatment.
Results due Q2/2020 - could be a big multi bagger if it passes.